Home > Quotes > BIIB > Guru Analysis > David Dreman

David Dreman Guru Analysis for Biogen Inc.

Get BIIB Alerts
*Delayed - data as of Jul. 19, 2019  -  Find a broker to begin trading BIIB now
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Assessments & Analysis Based on July 18, 2019 close price: $232.23

  for the Contrarian Investor based on the criteria of David Dreman. Return to BIIB Guru Analysis

All Star Guru Scorecard

Source Go Chart %
Peter Lynch 91%
Benjamin Graham 71%
Validea 36%
Motley Fool 32%
David Dreman 79%
Martin Zweig 77%
Kenneth Fisher 10%
James P. O'Shaughnessy 50%

Detailed Analysis

Guru Score: 79%


Medium to large-sized companies (the largest 1500 companies) should be chosen, because they are more in the protected eye. Furthermore, the investor is exposed to less risk of "accounting gimmickry", and companies of this size have more staying power. BIIB has a market cap of $45,028 million, therefore passing the test.


A company should show a rising trend in the reported earnings for the most recent quarters. BIIB's EPS for the past 2 quarters, (from earliest to most recent quarter) 4.85, 7.15 have been increasing, and therefore the company passes this test.


This methodology likes to see companies with an EPS growth rate higher than the S&P in the immediate past and a likelihood that this trend will continue in the near future. BIIB passes this test as its EPS growth rate over the past 6 months (0.00%) has beaten that of the S&P (-9.67%). BIIB's estimated EPS growth for the current year is (36.54%), which indicates the company is expected to experience positive earnings growth. As a result, BIIB passes this test.

This methodology would utilize four separate criteria to determine if BIIB is a contrarian stock. In order to eliminate weak companies we have stipulated that the stock should pass at least two of the following four major criteria in order to receive "Some Interest".


The P/E of a company should be in the bottom 20% of the overall market. BIIB's P/E of 9.95, , meets the bottom 20% criterion (below 10.60), and therefore passes this test.


The P/CF of a company should be in the bottom 20% of the overall market. BIIB's P/CF of 7.72 does not meet the bottom 20% criterion (below 5.92), and therefore fails this test.


The P/B value of a company should be in the bottom 20% of the overall market. BIIB's P/B is currently 3.28, which does not meet the bottom 20% criterion (below 0.94), and it therefore fails this test.


The P/D ratio for a company should be in the bottom 20% of the overall market (that is the yield should be in the top 20%). BIIB's P/D is not available, and hence an opinion cannot be rendered at this time.

This methodology maintains that investors should look for as many healthy financial ratios as possible to ascertain the financial strength of the company. These criteria are detailed below.


A prospective company must have a strong Current Ratio (greater than or equal to the average of it's industry [1.61] or greater than 2). This is one ident ifier of financially strong companies, according to this methodology. BIIB's current ratio of 2.84 passes the test.


A good indicator that a company has the ability to raise its dividend is a low payout ratio. The payout ratio for BIIB is 0.00%. Unfortunately, its historical payout ratio is not available. Nonetheless it passes the payout criterion, as this is a very low payout.


The company should have a high ROE, as this helps to ensure that there are no structural flaws in the company. This methodology feels that the ROE should be greater than the top one third of ROE from among the top 1500 large cap stocks, which is 17.54%, and would consider anything over 27% to be staggering. The ROE for BIIB of 33.64% is high enough to pass this criterion.


This methodology looks for pre-tax profit margins of at least 8%, and considers anything over 22% to be phenomenal. BIIB's pre-tax profit margin is 45.37%, thus passing this criterion.


The company in question should have a yield that is high and that can be maintained or increased. BIIB's current yield is not available (or one is not paid) at the present time, while the market yield is 2.62%. Hence, this criterion cannot be evaluated.


The company must have a low Debt/Equity ratio, which indicates a strong balance sheet. The Debt/Equity ratio should not be greater than 20% or should be less than the average Debt/Equity for its industry of 172.04%. BIIB's Total Debt/Equity of 42.97% is considered acceptable.

The names of individual investment advisors (i.e., the 'gurus') appearing ON THIS WEBSITE are for identification purposes ONLY. The names are used to identify the methodology as derived from the guru's published sources. The names of the individual gurus are not intended to suggest or imply any affiliation with or endorsement of, or even any agreement with the information displayed on this website personally by such gurus, or any knowledge or approval by such persons of the content on this website. All trademarks, service marks and trade names appearing on this website are the property of their respective owners, and are likewise used for identification purposes only.

The NASDAQ Stock Market, Inc. ("NASDAQ"), its affiliates, third party information providers, or any of these entities' officers, employees, directors, or agents have not: (1) passed on the merit of the information provided on this website or on any of these securities; or (2) endorsed or sponsored any of these securities. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. The information contained on this website is provided for informational purposes only. See Full Disclaimer Below
See Full Disclaimer